


### Notes


All rights reserved.

The illustrations are from Dr. Umbach's book and CD-ROM "Successfully Marketing Clinical Results: Winning in the Pharma Business", Gower Publishing, London, 2006


© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

2



















































<section-header><section-header><section-header><image><image><text><text><text><text>

Never neglect the specialists












































## **Calling the Other Treatment**

- Control
- Standard therapy
- Conventional therapy
- Reference substance

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

29

- Gold standard


A Convincing Message		
Concise Short and to the point		
Clear	Easily understandable	
Credible	Endorsed by reliable sources	
Consistent	Repeated in a uniform way	
Something your Customers Care about		
© Healthcare Marketing I	Dr. Umbach & Partner www.umbachpartner.com 30	




No Benefit

Unnecessary


Drop the details





Relevant





## The Doctor's Real Needs



The doctor is interested in Improving patients' health


36

Making patients happy

Giving state-of-the-art treatment

Saving precious time

Being financially successful






## **COMET: Scientific Data**

Carvedilol in Heart Failure

In the Carvedilol or Metoprolol European Trial (COMET), around 3000 people with chronic heart failure were assigned to receive twice-daily doses of carvedilol or metoprolol for around five years. Yearly mortality rates were 8.3% with carvedilol and 10.0% with metoprolol. Average life-expectancy was eight years for patients given carvedilol compared with 6.6 years for patients assigned metoprolol. 34% of patients assigned carvedilol died during the five-year study compared with 40% of patients assigned metoprolol.

Based on presentations and The Lancet, 5 July 2003



## **COMET: Message to Experts**


Carvedilol in Heart Failure

Results of a European study in this week's issue of *The Lancet* suggest that the beta-blocker carvedilol offers substantial survival benefit compared with another widely-used beta blocker for the treatment of chronic heart failure.

Based on presentations and The Lancet, 5 July 2003

40

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com



## **ACTION: Scientific Data**

#### Long-Acting Nifedipine in Angina

A Coronary Disease Trial Investigating Outcome with Nifedipine GITS (ACTION): Patients with treated stable symptomatic coronary disease: 3825 patients assigned to nifedipine and 3840 assigned to placebo

**Findings:** 310 patients allocated nifedipine died compared with 291 people allocated placebo (p=0.41). Primary endpoint rates per 100 patient-years were 4.6 for nifedipine versus 4.75 for placebo. With nifedipine, rate of death and any cardiovascular event or procedure was 9.32 per 100 patient-years versus 10.50 for placebo (p=0.0012)

Based on presentations and The Lancet published online August 31, 2004
© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com 42

## Your Suggestions?

#### Message to experts

Message to prescribing physicians

43

44

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

**Press release** 

# ACTION: Message to Experts Long-Acting Nifedipine in Angina

Addition of nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-free survival. Nifedipine GITS reduces the need for coronary angiography and interventions.

Based on presentations and The Lancet published online August 31, 2004

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

## **ACTION: Message to Physicians**

Long-Acting Nifedipine in Angina

A unique study due to its design, size and scientific validity

Proven safety and improved outcomes on top of best practice treatment: 11% additional risk reduction\*

\*Primary endpoint and interventions

Based on presentations and The Lancet published online August 31, 2004 © Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com 45


#### ACTION: Press Release New landmark study demonstrates additional benefits of lang-acting nifedipine ACTION is the first long-term randomised controlled clinical trial of an antianginal drug in ... Professor Philip Poole-Wilson, Chairman of the steering committee, presented the ACTION results. ACTION ... documents that a long-term treatment with nifedipine GITS significantly prolongs cardiovascular event and procedure-free survival,

46

48

when added to a best-practice therapy.

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com





## 4 'S': Scientific Data


Scandinavian Simvastatin Survival Study

Although noncardiac death rates were similar among the groups, the relative risk of mortality (from any cause) was decreased 30%, and the relative risk of coronary mortality was decreased 42% in the simvastatin arm.


Based on presentations and the article by Pedersen TR: Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol. 1998 Nov 26;82(10B):53T-56T




















## ONTARGET


Telmisartan was "noninferior" to ramipril. The combination of the two drugs was associated with more adverse events without an increase in benefit.

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com


55

N Engl J Med, April 10, 2008











#### **ONTARGET: Opinion Leader**

"This study is of clinical importance because it demonstrates that telmisartan is an effective and safe alternative to ramipril.

This means both patients and physicians have choices and can use telmisartan where appropriate with a high degree of confidence."

http://www.medscape.com/viewarticle/572259

Lead investigator of the trial, Dr Salim Yusuf (McMaster University, Hamilton, Ontario)

59

60

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com


## **Brand Visibility**

Brand name in study name?


Rename / modify the study name


© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

Sell the product, not the study

















































The Only One		
The only angiotensin receptor blocker with proven mortality and morbidity benefits in heart failure, irrespective of background therapy		
<b>CHARM: C</b> andesartan in <b>H</b> eart Failure - <b>A</b> ssessment of <b>R</b> eduction in <b>M</b> ortality and morbidity		
Atacand <sup>®</sup> is AstraZeneca's trademark for candesartan	AstraZeneca CHARM S	
© Healthcare Marketing Dr. Umbach & Part	ner www.umbachpartner.com 73	

A Precise Number		
Key conclusions from the Examplex trial in diabetic patients	The <b>3</b> key conclusions from the Examplex trial in diabetic patients	
© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com 74		


























'Magic' Words		
	Health	
	Value	
	Advantage	
	Benefit	
	Result	
I feel most comfortable with		
© Healthcare Mark	eting Dr. Umbach & Partner www	umbachpartner.com 81


Alternatives to "Prove"		
Avoid	Prefer	
• Prove	<ul> <li>Validate</li> <li>Document</li> <li>Confirm</li> <li>Highlight</li> <li>Emphasize</li> <li>Underline</li> </ul>	
© Healthcare Marketing Dr. Umbach & F		


Alternat	ives to "D	)ifference"
Your product is 20% superior		
Unclear	Better	Preferable
20% difference	20% increase	20% improve- ment
© Healthcare Marketing Dr. U	mbach & Partner www.um	bachpartner.com 83




Dictionary		
The ten most important words for marketing the trial are		
•	•	
Write your vocabulary		
Put in on the wall or computer		
© Healthcare Marketing Dr. Umbach & F	Partner www.umbachpartner.com 84	






























































## **Problem and Solution**

Diabetes is with your patients all day, every day.

**Now** there's an insulin that can work just as long. Examplex provides 24-hour coverage with just one administration.

Based on a real advertisement

99

## **Past and Present**


Many cancer patients suffer from bone-destroying activities associated with bone metastases.

**Until recently**, there was no effective treatment for bone metastases. **Now** biphosphonates can help improve bone strength in cancer patients.

100

102


© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com




## Edit a Scientific Text

This randomized clinical trial investigated the influence of substantin on the mortality of patients with breast cancer. The trial showed a significant difference between the treatment arms in favour of substantin.

Substantin significantly improves survival in breast cancer patients. The results of this randomized clinical trial clearly confirm the benefit of substantin.







## The Q & A Section

People like

Questions & Answers

105


Question

Why is this study important?


## Answer


This is the first study that ...

Expressing Figures		
0.2 %	Two in Thousand	
0 2 2 5 %	2.25 %	
80%	8 of 10	
950 000	About 1 million	
26 years	More than a quarter of a century	
Appears 📕	Appears 👕	
© Healthcare Marketing Dr. Umbach	a & Partner www.umbachpartner.com 106	



















# **Capitals and Lower Case**

THIS TRIAL CONFIRMS THAT SUBSTANTIN CAN IMPROVE SURVIVAL OF PATIENTS



Avoid capital letters

112


113

114

This trial confirms that substantin can improve survival of patients

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com





can improve survival of patients with advanced breast cancer

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

Underlining


This <u>trial confirms</u> that <u>substantin</u> can <u>improve survival</u> of <u>patients</u> with advanced <u>breast cancer</u>




Avoid underlining


This trial confirms that substantin can improve survival of patients with advanced breast cancer

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com












### Layout

Composition of text and image


© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

How do you arrange the elements?


118














































Recall with Substantin 1					
Increase	Constant	Decrease			
50%	48%	2%			
Sequence of columns?					
© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com 128					






























































Appropriate Images				
	Picture			
	Illustration			
	Symbol			
	Icon			
Choose a visual relevant to your message				
© Healthcare	Marketing Dr. Umbach & Partner www	ww.umbachpartner.com 142		



















# Find Images on the Web

Type a keyword and let a search engine (*Google*) find


- suitable words
- suitable pictures

www.inmagine.com www.agefotostock.com


© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com 147

















### Human Interest Story: Press Briefing


Case history: Patrick, age 72 Location: United Kingdom Medical History: A long history of atrial fibrillation. Right sided ischemic stroke after a prolonged episode of atrial fibrillation. Associated conditions: Left-sided hemiplegia and compromised mobility, loss of creative ability, neuropathic pain


Patrick was a talented, award-winning composer of concert music until his embolic stroke. He is best known for his theme to Sherlock Holmes on TV ...


His wife Caroline describes the effect of Patrick's stroke on their life: "I became a carer ... he was doubly incontinent .. He had to be fed through a tube and everything" © Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com 152
























Use identical vocabulary and terminology in

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com

157

- Publications
- Press releases
- Advertisements



























Ask for the Budget				
200 000 Euro A worthwhile investment	Your project is worth it			
© Healthcare Marketing Dr. Umbach &	& Partner www.umbachpartner.com	166		

























# **Rise to New Heights**



No one can predict to what heights you can soar

174

Even you will not know until you spread your wings

© Healthcare Marketing Dr. Umbach & Partner www.umbachpartner.com



